Twist Bioscience Financials - Benzinga

Twist Bioscience Corp

TWSTNASDAQ

Trade with Public

Trade with Public

$158.40

-6.20-3.77%

最終更新: Sep 23, 11:20 AM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Twist Bioscience Financials

Twist Bioscience (TWST) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Twist Bioscience Q3 EPS $(0.56) Misses $(0.50) Estimate, Sales $118.376M Beat $114.490M Estimate

Benzinga Newsdesk

PRO
Twist Bioscience Raises FY2026 Sales Guidance from $442.000M-$447.000M to $456.000M-$457.000M vs $446.103M Est

Twist Bioscience (NASDAQ:TWST) raises FY2026 sales outlook from $442.000 million-$447.000 million to $456.000 million-$457.000 million vs $446.103 million estimate.

Benzinga Newsdesk

PRO
Twist Bioscience Sees Q4 Sales $123.000M-$124.000M vs $117.546M Est

Twist Bioscience (NASDAQ:TWST) sees Q4 sales of $123.000 million-$124.000 million vs $117.546 million analyst estimate.

Benzinga Newsdesk

These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results

Twist Bioscience Corp (TWST) reported Q2 loss but exceeded sales guidance. CEO expects profitability and raised FY sales guidance. Analysts raise price targets.

Avi Kapoor

AI-Driven Demand Boosts Twist Bioscience Sales, But Loss Widens

Twist Bioscience posts wider Q2 loss, beats revenue estimates, raises FY26 outlook, and expands gene portfolio.

Vandana Singh

PRO
Twist Bioscience Q2 Adj. EPS $(0.59) Misses $(0.48) Estimate, Sales $110.715M Beat $107.657M Estimate

Twist Bioscience (NASDAQ:TWST) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.48) by 22.92 percent. This is a 10.61 percent increase over losses of $(0.66) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved